Johnson & Johnson (JNJ) Projected to Post Earnings on Tuesday

Key Points

• Johnson & Johnson is set to release its Q3 2025 earnings on October 14, 2025, with analysts predicting earnings of $2.78 per share and revenue of $23.7258 billion.
• The company recently reported Q2 earnings of $2.77 per share, exceeding expectations, along with a 5.8% year-over-year revenue increase.
• Johnson & Johnson's stock analysts have varying target prices, with Citigroup raising theirs from $185 to $200, reflecting optimism about the company's performance.

Johnson & Johnson (NYSE:JNJ - Get Free Report) is expected to be releasing its Q3 2025 results before the market opens on Tuesday, October 14th. Analysts expect Johnson & Johnson to post earnings of $2.78 per share and revenue of $23.7258 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS.Interested persons are encouraged to explore the company's upcoming Q3 2025 earningoverview page for the latest details on the call scheduled for Tuesday, October 14, 2025 at 8:30 AM ET.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company's quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm earned $2.82 earnings per share. On average, analysts expect Johnson & Johnson to post $11 EPS for the current fiscal year and $11 EPS for the next fiscal year.

Johnson & Johnson Price Performance

Shares of JNJ opened at $188.23 on Tuesday. The company has a market cap of $453.32 billion, a price-to-earnings ratio of 20.13, a price-to-earnings-growth ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $189.92. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The company has a 50 day moving average of $176.62 and a two-hundred day moving average of $163.00.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the firm's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company's stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Semmax Financial Advisors Inc. raised its holdings in shares of Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company's stock worth $31,000 after purchasing an additional 72 shares during the last quarter. WealthCollab LLC raised its holdings in shares of Johnson & Johnson by 9.9% during the second quarter. WealthCollab LLC now owns 924 shares of the company's stock worth $141,000 after purchasing an additional 83 shares during the last quarter. Rakuten Securities Inc. raised its holdings in shares of Johnson & Johnson by 8.0% during the second quarter. Rakuten Securities Inc. now owns 1,140 shares of the company's stock worth $174,000 after purchasing an additional 84 shares during the last quarter. Wealth Group Ltd. raised its holdings in shares of Johnson & Johnson by 12.8% during the second quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock worth $226,000 after purchasing an additional 168 shares during the last quarter. Finally, Darwin Wealth Management LLC purchased a new position in shares of Johnson & Johnson during the second quarter worth $252,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have weighed in on the stock. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Barclays raised their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. UBS Group set a $198.00 target price on shares of Johnson & Johnson in a research note on Friday. Finally, Citigroup raised their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a report on Thursday, August 21st. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $189.12.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.